AgomAb Therapeutics NV

AgomAb Therapeutics NV की हमारे पास उपलब्ध सबसे नई तिमाही

कंपनी की अपनी 6-K रिपोर्ट से।

प्रबंधन ने क्या कहा

“In the first half of 2026, we continued to execute on our clinical and operational strategy, and we are on track with the clinical read-outs and trial initiations of ontunisertib and AGMB-447 expected later this year,”

विज्ञप्ति से हूबहू उद्धृत, और तभी दिखाया गया जब रिपोर्ट उसे किसी नामित व्यक्ति से जोड़ती है।

AgomAb Therapeutics NV क्या करती है

Crohn’s Disease Crohn’s disease is a chronic progressive disease of the gastrointestinal tract. It is estimated that approximately 46% of patients with Crohn’s disease have fibrosis of the gastrointestinal tract, resulting in stricture formation and intestinal obstructions, most frequently in the terminal ileum. These strictures can cause obstructive symptoms leading to dietary change, malnutrition and surgery. Despite the large unmet medical need, there are no approved pharmacological therapies for FSCD.

कंपनी का अपना विवरण, जैसा विज्ञप्ति के अंत में दिया गया है।